Iranian medical products enter international markets

The company, Kitotec, uses nanotechnology and biocompatible materials to develop products for infection control, bleeding management and wound healing. Its portfolio covers applications ranging from wounds and burns to surgery, dentistry and chronic wound care.

Nanotechnology can help improve infection control and enable the design of biocompatible materials for wound healing. Meanwhile, effective hemostatic materials are particularly important in trauma, surgery and severe bleeding.

Silver nanoparticle-based disinfectants

One of Kitotec’s key product lines is Silosept, a range of disinfectants based on silver nanocolloids. These products are designed to combat a broad range of pathogens, including bacteria and fungi.

The Silosept range includes formulations for disinfecting wounds and burns, hands, surfaces, medical equipment and skin. Their antimicrobial activity is associated with the properties of silver nanoparticles.

According to the described mechanism, silver nanoparticles interact with microbial cell walls and membranes. This interaction can disrupt normal cellular functions and ultimately lead to the destruction of microorganisms.

Another proposed mechanism is the inhibition of microbial growth, which may help control the spread of infection.

Silosept products have been evaluated by reference laboratories and in clinical studies in accordance with international standards. Reported test results indicate no systemic toxicity, skin irritation or acute inhalation toxicity. The concentration of the active ingredient has also been reported to fall within a safe range.

Products for rapid bleeding control

Severe bleeding remains a major challenge in emergencies, surgery and trauma care. To address this need, Kitotec has developed a range of hemostatic products under the trade names Kitohim, Kitosel, Hemogaz and Bon Hem.

These products are designed to control arterial, venous and capillary bleeding. Their applications include trauma care, surgery, dentistry and nosebleeds.

The products work by absorbing blood plasma and increasing the concentration of clotting factors at the bleeding site. This process can accelerate clot formation.

An increase in the local concentration of platelets and red blood cells also contributes to the formation of platelet complexes and helps stop bleeding.

The products can also be used in patients with coagulation disorders, such as hemophilia. According to the company, tests have shown no cytotoxicity, sensitization or irritation. Clinical studies have also evaluated their effectiveness in accordance with international standards.

Bioactive dressings for wound healing

Another part of the company’s portfolio focuses on wound care. Kitotec has developed bioactive dressings based on chitosan, a natural material derived from crustacean shells and the cell walls of certain fungi.

Chitosan is attracting interest in medical product development and tissue engineering because of its biocompatibility, antimicrobial properties and potential to support wound healing.

Kitotec’s bioactive dressings are designed to create more favorable conditions for tissue repair. According to the described mechanism, they may influence healing by activating immune cells and factors involved in tissue regeneration.

Maintaining appropriate moisture levels at the wound site is another key feature of these dressings. According to the information provided, studies have reported a 70% reduction in wound treatment duration in connection with this feature.

The dressings are designed for various types of wounds. These include acute wounds caused by burns, traumatic injuries and surgery, as well as chronic wounds such as diabetic foot ulcers, pressure ulcers and vascular ulcers.

Safety testing and clinical evaluation

Developing medical products requires careful assessment of safety and biocompatibility, in addition to demonstrating the intended performance.

Kitotec says its products are manufactured and evaluated in accordance with relevant production requirements and testing procedures. Assessments include tests for cytotoxicity, sensitization and irritation.

Combining these evaluations with clinical studies helps assess product performance and safety under different conditions. These steps are an important part of developing and bringing medical products to market.

Presence in international markets

The company’s products are available in Iran and international markets. Their development could help meet some domestic demand for advanced medical products while expanding the presence of Iranian-made products abroad.

The products aim to reduce infection-related complications, support faster bleeding control and accelerate wound healing. If their effectiveness and safety are established through relevant studies, such technologies could also help reduce treatment costs and hospital stays.